Date
- 2026 (21)
- 2025 (32)
- 2024 (18)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (36)
- 2014 (10)
- 2013 (12)
- 2012 (3)
- 2011 (6)
- 2010 (27)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (10)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (3)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (12)
Sponsor content
577 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryRhapsido has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Rhapsido contains the active ingredient remibrutinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RHAPSIDO remibrutinib 25 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CEAHANI nilotinib 150 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CEAHANI nilotinib 200mg capsules blister pack.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVLOIRE CR 400 carbamazepine 400 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVLOIRE CR 200 carbamazepine 200 mg tablet blister pack.
-
Designation or determinationOrphan drug